‌

US Patent 7595389 siRNA targeting casitas B cell lymphoma-B (CBL-B)

Patent 7595389 was granted and assigned to Dharmacon, Inc. on September, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Dharmacon, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7595389

Patent Inventor Names

William Marshall0

Devin Leake0

Stephen Scaringe0

Steven Read0

Anastasia Khvorova0

Angela Reynolds0

Date of Patent

September 29, 2009

Patent Application Number

11880628

Date Filed

July 23, 2007

Patent Primary Examiner

‌

Richard Schnizer

Patent abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CBL-B.